Home › AiCuris and Merck Announce Publication in New England Journal of Medicine of Phase 2 Clinical Trial Results of Investigational Antiviral Agent Letermovir in Bone Marrow Transplant Patients
 

Keywords :   


AiCuris and Merck Announce Publication in New England Journal of Medicine of Phase 2 Clinical Trial Results of Investigational Antiviral Agent Letermovir in Bone Marrow Transplant Patients

2014-05-08 15:00:00| Merck.com - Research & Development News

Dateline City: WUPPERTAL, Germany & WHITEHOUSE STATION, N.J. WUPPERTAL, Germany & WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--AiCuris and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the publication of results from a Phase 2 clinical trial evaluating the safety and efficacy of letermovir, an investigational, oral antiviral agent for the prevention of human cytomegalovirus (CMV) infection in patients receiving bone marrow transplant. Language: English Contact: MerckMedia:Caroline Lappetito, 267-305-7639orInvestors:Carol Ferguson, 908-423-4465orAiCurisMedia:Katja Woestenhemke, +49-202-317-63-1176 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: results publication journal agent

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
20.05Sheboygan Paint Company Appoints New Technical Sales Representative
20.05Canada invests over $9.6M to prevent, prepare for African swine fever
20.05Dabbagh Named General Manager of Waldencast Ventures Glaze Brand
20.05Several pork priorities secured in House Farm Bill
20.05BT scraps digital landline switch deadline
20.05Essie Introduces Nail Art Studio
20.05Ilia Beauty Introduces Vegan Lip Sketch Hydrating Crayon
20.05Summer interest rate cut possible, says Bank deputy
More »